| 1.09 -0.04 (-3.54%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.41  |
1-year : | 1.51 |
| Resists | First : | 1.21 |
Second : | 1.29 |
| Pivot price | 1.19 |
|||
| Supports | First : | 1.07 | Second : | 0.89 |
| MAs | MA(5) : | 1.13 |
MA(20) : | 1.21 |
| MA(100) : | 1.29 |
MA(250) : | 1.54 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 15.5  |
D(3) : | 10.6 |
| RSI | RSI(14): 24.6 |
|||
| 52-week | High : | 2.74 | Low : | 1.07 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ENZ ] has closed above bottom band by 1.5%. Bollinger Bands are 46.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.12 - 1.12 | 1.12 - 1.13 |
| Low: | 1.05 - 1.06 | 1.06 - 1.07 |
| Close: | 1.08 - 1.09 | 1.09 - 1.1 |
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
Thu, 14 Mar 2024
Enzo Biochem (NYSE:ENZ) shareholders have endured a 69% loss from investing in the stock three years ago - Yahoo Finance
Wed, 13 Mar 2024
Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update - Yahoo Finance
Tue, 27 Feb 2024
Enzo Biochem Executives Receive Raises and Equity Rewards - TipRanks.com - TipRanks
Thu, 01 Feb 2024
Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments - GlobeNewswire
Mon, 29 Jan 2024
Here's Why Laughing Water Capital Sold Enzo Biochem Inc (ENZ) - Yahoo Finance
Fri, 06 Oct 2023
Enzo Biochem (NYSE:ENZ) shareholders have endured a 63% loss from investing in the stock five years ago - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 51 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 24.1 (%) |
| Held by Institutions | 39.5 (%) |
| Shares Short | 721 (K) |
| Shares Short P.Month | 715 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.39 |
| Profit Margin | 99.2 % |
| Operating Margin | -25.6 % |
| Return on Assets (ttm) | -16.6 % |
| Return on Equity (ttm) | -45.1 % |
| Qtrly Rev. Growth | 13.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.64 |
| EBITDA (p.s.) | -0.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -2.32 |
| PEG Ratio | 0 |
| Price to Book value | 0.77 |
| Price to Sales | 1.7 |
| Price to Cash Flow | -1.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|